SUBSCRIBE
SUBSCRIBE
News   Drug Development

Mochida Pharmaceuticals Completes Early Phase II Clinical Trial Of Epadel Indicated For Alzheimer’s Disease

December 15, 2005 | 
1 min read
Tokyo (JCN) Dec 15, 2005 - Mochida Pharmaceutical has completed an early phase II clinical trial of Epadel, which is targeted at Alzheimer's disease. Epadel is the company's proprietary agent used in the treatment of hyperlipemia.
Clinical research Phase 2 Asia
MORE ON THIS TOPIC
Glowing light bulb on spring appearing from red box. Creativity, innovation and aha moment concept. Flat design. EPS 8 vector illustration, no transparency
IPO
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
July 21, 2026
 · 
3 min read
 · 
Gabrielle Masson
Psychology, Dream, Mental Health concept illustration. Brain, neuroscience and creative mind poster, cover. Vector modern illustration
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
July 20, 2026
 · 
3 min read
 · 
Heather McKenzie
Man jumping, running, and winner holding trophy. Competition, challenge, risk and reward concept. Vector illustration.
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
July 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hand drawing light bulb and tangled ball, suggesting innovation and challenges
Drug Development
India’s life sciences sector at turning point for innovation: Report
July 17, 2026
 · 
2 min read
 · 
Angela Gabriel